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Abstract Breast cancer is the most common cancer type. In
several studies, hints have been provided that there is a corre-
lation between selenium deficiency and the incidence of breast
cancer. Findings of these published reports are, however,
inconsistent. This study serves as a pioneering study aiming
at combining the results of studies using a meta-analytic
method. A total of 16 articles published between 1980 and
2012 worldwide were selected through searching PubMed,
Scopus, and Google scholar databases, and the information
were analyzed using a meta-analytic method [random effects
model]. I2 statistics were used to examine heterogeneity. The
information was then analyzed by STATA version 12. In this
study, due to the non-uniform methods used to measure sele-
nium concentrations, selenium levels were measured in the
various subgroups in both case and control groups. There
were significant correlations between selenium concentration
and breast cancer [P<0.05]. Hence, the mean risk differenti-
ating criteria were estimated to be 0.63 [95 % confidence
interval [95% CI] 0.93 to 0.32] in serum and toenails.
Subgroup analysis showed that the value in toenails was
−0.07 [95% CI −0.16 to 0.03] and in serum −1.04 [95% CI
1.71 to −0.38]. In studies in which selenium concentrations
were measured in serum, a significant correlation was ob-
served between selenium concentration and breast cancer. In
contrast, in studies in which selenium concentration was mea-
sured in toenails, the correlation was not significant. There-
fore, the selenium concentration can be used as one predictor
for breast cancer.
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Introduction
Breast cancer is the most frequent cancer type in women in
developed countries and in some developing countries [1–4];
it is even considered the second cause of death for women. It is
so frequent that in 2008, 1.38 million new breast cancers were
reported to have been diagnosed. The mortality of breast
cancer worldwide is estimated to be 6 to 29 cases per
100,000 [5]. An increasing number of studies have focused
on the relation between nutrition and breast cancer. Selenium
has been reported to have chemo-preventive properties and
anti-carcinogenic activity [6]. However, in many studies, it
has shown a relation between selenium and breast cancer [7].
Selenium is an essential and unique trace element which has a
crucial role in reproduction, toxicity, antioxidant, and anti-
aging activities and can stimulate DNA reproduction. Seleni-
um plays an important role for many degenerative conditions
such as inflammatory, cardiovascular, and neurological dis-
eases. As a function of the presence of selenium, infections
have also been prevented in laboratory experiments, clinical,
and epidemiological data [8]. However, in the case of the
relation between selenium and breast cancer, there has been
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much controversy. There have been some epidemiologic stud-
ies evaluating breast cancer risk in association with selenium
levels [9–12]. However, other studies have failed to confirm
these findings [13, 14, 16]. Duo to the case-control studies,
selenium concentration in toenails has not been shown to be
related to breast cancer, but significant correlations have been
found for serum [17]. Therefore, the likelihood of an inverse
correlation between selenium and breast cancer must be in-
vestigated for better a prophylaxis and diagnosis of breast
cancer.
The main aim of the present study is, thus, to con-
duct a systematic review and a meta-analysis to shed
more light on the relationship between selenium levels
and breast cancer.
Methods
Study Selection
This article was written according to the PRISMA guidelines
[18]. The findings are based on theses and articles which were
published in national and international journals. We searched
the medical literature published in English in databases in-
cluding Google scholar, PubMed, ISI Web of Science, and
Scopus between 1980 and 2012. Literature searches were
applied by using the keywords selenium, serum, breast cancer,
meta-analysis, and related words. Qualified studies included
epidemiologic research reports measuring the correlation be-
tween selenium and breast cancer risk by measuring selenium
concentrations in any of the following biological sample
specimens: blood/serum and toenails. All papers which in-
cluded keywords in their titles or abstracts were included in
the initial list, and other irrelevant articles were crossed out.
The most important biases in meta-analysis are publication
bias and selection bias. Publication bias was checked using
Eger test. To reduce the possibility of selection bias in this
study, criteria were clearly defined and studied, and data
collection in each study was selected by two researchers
independently, and final list was chosen by consensus.
Then, an information checklist for research papers
consisting of first author’s last name; year of publica-
tion; country wherein the study was carried out; mean
age of the participants, sample size, selenium concen-
tration; odds ratio [OR] estimates with 95 % confidence
interval [CI]; and mean difference were prepared for the
final evaluation. Information on the type of selenium
measurement was also extracted from all the qualified
publications, whenever possible. Studies were excluded
if they were not written in English, if they presented
insufficient data, if they were mere reviews, or if they
were not epidemiologic studies.
Statistical Analysis
Studies were combined based on the sample size, means, and
standard deviations. Because of the low number of studies used
and because these studies had been published in prestigious
journals, quality criteria were not included in the analysis. The
average variance was calculated using the formula of two
integrated variance. The mean difference was computed using
the formula d ¼ x1−x2s in which x1 is the case mean, x2 is the
control mean, S is the pooled sample standard deviation defined
as s ¼
ﬃﬃﬃﬃ
s2
p
where it is calculated using s2 ¼ n2−1ð Þs21þ n2−1ð Þs22n1þn2
were the variances of the case group and control groups, respec-
tively, n1 and n1 equals the number of participants in each group
[19]. In order to evaluate heterogeneity of the studies, Cochran
test and the I2 index were used. Due to significant heterogeneity
in the studies, a model with random effects was used. In order to
examine publication bias, Begg’s Plot and regressions method
were used. A P value of less than 5% [P<0.05] was considered
as a significant heterogeneity test. Sensitivity analyses were pre-
specified. Statistical analyses were performed using STATA
version 12.
Results
The initial literature search identified 120 publications. Based
on these steps, in the first search, 120 studies that were
120 of study identified through Google scholar, 
PubMed and Scopus database searching 
96 of records after duplicates removed 
24 of records screened  4 of records 
excluded 
20 of full-text articles assessed 
for eligibility 
18 of studies included in qualitative 
synthesis 
16 of studies included in quantitative 
synthesis 
(meta-analysis) 
2 excluded Lack of 
enough information  
Fig. 1 Study flowchart
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published between 1980 and 2012 were selected. Duplicate
articles were excluded, and 24 study abstracts were analyzed.
After this stage, 20 articles which included initial data were
fully studied [Fig. 1]. The standard unit for measuring seleni-
um concentrations in many articles was microgram per liter
[μg/L] and in some of them was microgram per gram [μg/g].
However, all studies were analyzed in terms of micrograms
per liter. Summary characteristics of the 16 studies that were
included in this analysis are presented in Table 1.
After excluding duplicates and other publications ac-
cording to the selection criteria, 12 case-controls and four
case-cohort studies that examined the association between
selenium levels and breast cancer were identified and used
in the analysis. The studies included involved 6,013 partic-
ipants. In nine studies, selenium status was based on anal-
ysis of serum, whereas in the remaining seven, toenail was
the sample specimen used. Also in one study, plasma sele-
nium status was used. Eight studies showed a significant
NOTE: Weights are from random effects analysis
Overall  (I-squared = 97.4%, p = 0.000)
J.J Strain (2009)
L.Rejali (2007)
HSIEN WEN KUO (1999)
Schrauzer GN (1985)
Study
M.A Bakir (2004)
J.Fu Feng (2012)
K Charalabopoulos (2006)
P.Singh (2005)
Schrauzer GN (1985)
M.Moradi (2008)
ID
van 't Veer P (1990)
-1.04 (-1.71, -0.38)
-0.16 (-0.43, 0.12)
-0.84 (-1.21, -0.47)
-0.89 (-1.36, -0.41)
-0.88 (-1.42, -0.35)
-1.42 (-1.82, -1.01)
-0.89 (-1.39, -0.39)
-4.20 (-4.61, -3.80)
-0.06 (-0.28, 0.16)
-1.74 (-2.24, -1.25)
-0.15 (-0.57, 0.26)
SMD (95% CI)
-0.27 (-0.53, -0.01)
100.00
9.26
9.15
8.98
8.88
%
9.09
8.94
9.09
9.32
8.94
9.08
Weight
9.28
0-4.61 4.61
Fig. 2 Meta-analysis of the
association of serum selenium
with breast cancer risk. Square
represents effect estimate of
individual studies with their 95 %
confidence intervals with size of
squares proportional to the
weight assigned to the study in the
meta-analysis. In this chart,
studies are stored in order of the
year of publication and author’s
names, based on a random effects
model
NOTE: Weights are from random effects analysis
Overall  (I-squared = 43.9%, p = 0.098)
H.D Foster (1993)
S.Mannisto (2000)
Suzana S (2009)
Hunter DJ (1990)
P.P.H.Van Noord (1993)
Study
ID
van 't Veer P (1990)
van den Brandt PA (1994)
-0.07 (-0.16, 0.03)
-0.04 (-0.25, 0.17)
-0.19 (-0.34, -0.05)
-0.68 (-1.34, -0.01)
0.01 (-0.12, 0.14)
0.17 (-0.10, 0.43)
SMD (95% CI)
-0.12 (-0.34, 0.09)
-0.06 (-0.17, 0.06)
100.00
13.09
19.00
1.92
21.01
9.49
%
Weight
12.45
23.04
0-1.34 1.34
Fig. 3 Meta-analysis of the
association of selenium
concentration in toenails with
breast cancer risk. Square
represents effect estimate of
individual studies with their 95 %
confidence intervals with size of
squares proportional to the
weight assigned to the study in the
meta-analysis. In this chart,
studies are stored in order of the
year of publication and author’s
names, based on a random effects
model
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decrease in the risk of breast cancer among individuals with
higher selenium levels. Eight other studies reported no
significant inverse associations between selenium status
and breast cancer. In studies which included fewer controls
than cases, power problem was solved by increasing the
number of samples.
Selenium concentrations were measured in serum, toenails,
and erythrocyte. The difference between selenium concentra-
tions in the studies, in which selenium concentrations were
measured in serum, based on random effects in case and
control groups was −1.04 μg/L [95 % CI 1.71 to 0.38], this
value for toenails was −0.07 [95 % CI 0.16 to 0.03], and in
general, integration of data from the two groups and also with
a hair sample was −0.63 [95 % CI −0.93 to −0.32]. Confi-
dence intervals for each study and for each of the studies based
on random effects are given in Figs. 1, 2, and 3. These charts
are given based on years of research and the author’s name.
Publication bias was detected by drawing Begg’s funnel plot
in the meta-analysis. This diagram shows that there is a
publication bias (cp=0.008); this means that it is possible that
studies with the negative results have not been published
(Fig. 5).
NOTE: Weights are from random effects analysis
Overall  (I-squared = 96.4%, p = 0.000)
L.Rejali (2007)
J.Fu Feng (2012)
P.Singh (2005)
J.J Strain (2009)
ID
Hunter DJ (1990)
Study
M.A Bakir (2004)
S.Mannisto (2000)
P.P.H.Van Noord (1993)
Suzana S (2009)
van 't Veer P (1990)
H.D Foster (1993)
HSIEN WEN KUO (1999)
M.Moradi (2008)
van 't Veer P (1990)
van 't Veer P (1990)
van den Brandt PA (1994)
Schrauzer GN (1985)
Schrauzer GN (1985)
K Charalabopoulos (2006)
-0.63 (-0.93, -0.32)
-0.84 (-1.21, -0.47)
-0.89 (-1.39, -0.39)
-0.06 (-0.28, 0.16)
-0.16 (-0.43, 0.12)
SMD (95% CI)
0.01 (-0.12, 0.14)
-1.42 (-1.82, -1.01)
-0.19 (-0.34, -0.05)
0.17 (-0.10, 0.43)
-0.68 (-1.34, -0.01)
0.04 (-0.22, 0.30)
-0.04 (-0.25, 0.17)
-0.89 (-1.36, -0.41)
-0.15 (-0.57, 0.26)
-0.27 (-0.53, -0.01)
-0.12 (-0.34, 0.09)
-0.06 (-0.17, 0.06)
-0.88 (-1.42, -0.35)
-1.74 (-2.24, -1.25)
-4.20 (-4.61, -3.80)
100.00
5.24
4.92
5.52
5.43
Weight
5.62
%
5.16
5.60
5.44
4.45
5.45
5.53
4.98
5.14
5.45
5.52
5.63
4.84
4.93
5.15
0-4.61 4.61
Fig. 4 Meta-analysis of the
association of selenium with
breast cancer risk. Square
represents effect estimate of
individual studies with their 95 %
confidence intervals with size of
squares proportional to the
weight assigned to the study in the
meta-analysis. In this chart,
studies are stored in order of the
year of publication and author’s
names, based on a random effects
model
Begg's funnel plot with pseudo 95% confidence limits
SMD
s.e. of: 
0 .2 .4
-4
-2
0
Fig. 5 Begg’s funnel plot for
publication bias
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Discussion
In the present meta-analysis, the relationship between selenium
levels and breast cancer was examined. Combining the results
from 16 epidemiologic studies, which applied individual levels
of seleniummeasured in serum or toenails (P=0.000), indicated
that there is a significant decrease in the risk of breast cancer
associated with high levels of selenium (Fig. 4). However,
serum and toenail status of selenium were examined. Analysis
of selenium concentrations in serum indicated that there is a
reverse association between a selenium level and the risk of
breast cancer (P=0.002). On the other hand, the results obtained
from toenails showed no association between breast cancer and
toenail selenium levels (P=0.17).
In a review of an article conducted by Rayman (2005), the
relationship between selenium and cancer was examined. This
review showed that selenium has anti-cancer activities [7].
Although little is known about the role of selenium for breast
cancer, many studies have shown that there is an association
between selenium diet and cancer risk [6, 10, 23]. Selenium
nutritional supplements may reduce incidence of cancer [21].
Cohort study in Sweden suggested that selenium was inverse-
ly associated with breast cancer mortality [24]. Scherauzer
et al. has shown that selenium concentrations in women with
benign fibrocystic disease were lower than those of women
with and without breast cancer [10]. Feng et al. identified
significant differences in serum levels of selenium between
breast cancer patients and control groups [31]. In a systematic
review and meta-analysis conducted by Dennert et.al, the
association between baseline selenium levels and incidence
of cancer in general, and breast cancer in particular, were
examined. This study showed no association between seleni-
um and the risk of breast cancer. However, one significant
limitation of Dennert et al.’s study compared to our study is
the paucity of studies and the relatively small number of
subjects in each study which could have affected the results
of the analysis [13]. The results obtained in a group of Dutch
white women indicated that there is no significant association
between the total amount of selenium in diet, short-term
[plasma], and long-term markers of selenium [erythrocytes,
toenails] and breast cancer [15]. Several RCT investigations
have also failed to detect any association between selenium
and breast cancer [27–30].
The highest selenium status refers to concentrations of
selenium in toenails of ∼0.9 μg/g and in serum of
∼230 μg/L, or higher [9, 5].
Although the specific selenium anti-carcinogenic mecha-
nisms are not yet fully known, multiple mechanisms have
been proposed to explain these selenium characteristics. Ac-
tually, antioxidant properties of selenoenzymes are relevant in
carcinogenesis and tumor progression [22]. Selenium is pres-
ent in glutathione peroxidase, which protects the DNA and
main cellular components from the damage of the free radicals
by decreasing ROS generation; in this way, levels of dietary
antioxidant vitamins and carotenoids and SNP that affect
antioxidant selenoproteins modify the effect of selenium on
cancer risk [20, 25, 27]. Additionally, selenium enhances
tumor-suppressor protein p53 activates that inhibits prolifera-
tion, increases DNA repair, and promotes apoptosis [7, 34].
Limitations
The limitations and weaknesses of the current study were
largely related to the methodology of the reviewed studies.
Some of these weaknesses are as follows:
1. Lack of a uniformmethod of measurement for the variances.
2. Selection of women referring to the health centers com-
pared to a random selection.
3. Lack of information about nutrition and lifestyle of the
participants.
4. Various kinds of screening methods and lack of a uniform
standard unit for measuring selenium concentrations in
different articles.
5. One significant limitation was the lack of access to some
relevant studies.
Conclusion
In conclusion, this meta-analysis based random effect model
supports an inverse association between selenium concentra-
tion and breast cancer risk (P=0). Therefore, the selenium
concentration can be used as a variable predictor for breast
cancer (P=0). In summary, the results of this study can be
used in clinical trials and randomized clinical trials for the
prevention of breast cancer through using high levels of
selenium in diet.
At the end, smoking, obesity, alcohol, inactivity, and stress
are other relevant risk factors for breast cancer.
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